Skip to main content

Biomarkers Unlimited: Accept Only OUR Substitutes!


Sounds great, doesn't it? Getting clinical trial results quickly has so much going for it. Information sooner! More affordable trials!

Substituting outcomes that can take years, or even decades, to emerge, with ones you can measure much earlier, makes clinical research much simpler. This kind of substitute outcome is called a surrogate (or intermediate) endpoint or outcome.

Surrogates are often biomarkers - biological signs of disease or a risk factor of disease, like cholesterol in the blood. They are used in clinical care to test for, or keep track of, signs of emerging or progressing disease. Sometimes, like cholesterol, they're the target of treatment.

The problem is, these kinds of substitute measures aren't always reliable. And sometimes we find that out in the hardest possible way.

The risk was recognized as soon as the current methodology of clinical trials was being developed in the 1950s. A famous statistician who was key to that process, Austin Bradford-Hill, put it bluntly: if the "rate falls, the pulse is steady, and the blood pressure impeccable, we are still not much better off if unfortunately the patient dies."

That famously happened with some drugs that controlled cardiac arrhythmia - irregular heartbeat that increases the chances of having a heart attack. On the basis of ECG tests that showed the heartbeat was regular, these drugs were prescribed for years before a trial showed that they were causing tens of thousands of premature deaths, not preventing them. That kind of problem has happened too often for comfort.

It happened again this week - although at least before the drug was ever approved. A drug company canceled all its trials for advanced gastric (stomach) cancer of a new drug. The drug is called Rilotumumab. Back in January, it was a "promising" treatment, billed as bringing "new hope in gastric cancer." It got through the early testing phases and was in Phase III trials - the kind needed to get FDA approval.

But one phase III trial, RILOMET-1, quickly showed an increase in the number of deaths in people using the drug. We don't know how many yet - but it was enough for the company to decide to end all trials of the substance.

This drug targets a biomarker associated with worse disease outcomes, an area seen by some as transforming gastric cancer research and treatment. Others see considerable challenges, though - and what happened to the participants in the RILOMET-1 trial underscores why.

There is a lot of controversy about surrogate outcomes - and debates about what's needed to show that an outcome or measure is a valid surrogate we can rely on. They can lead us to think that a treatment is more effective than it really is.

Yet a recent investigative report found that cancer drugs are being increasingly approved based only on surrogate outcomes, like "progression-free survival." That measures biomarker activity rather than overall survival (when people died).

It can be hard to recognize at first, what's a surrogate and what's an actual health outcome. One rule of thumb is, if you need a laboratory test of some kind, it's more likely to be a surrogate. Whereas symptoms of the disease you're concerned, or harm caused by the disease, are the direct outcomes of interest. Sometimes those are specified as"patient-relevant outcomes."

Many surrogate outcomes are incredibly important, of course - viral load for HIV treatment and trials for example. But in general, when clinical research results are based only on surrogates, the evidence just isn't as strong and reliable as it is for the outcomes we are really concerned about.

~~~~

See also, Statistically Funny on "promising" treatments.

Comments

Post a Comment

Popular posts from this blog

Austerity-A Fancy Word for Destitute.

The reason for this post is not for the folks who have been caught in the first wave of personal economic hard reality, but the next wave. Regardless of the optimism espoused by grinning leaders and sycophant press, we are entering the final stage of global economic collapse. It began in 2008 and was forestalled for five years with fudge putty, but the weight of global indebtedness cannot be propped any longer and the final crunch is imminent. Austerity measures herald the final throes.  Indications of coming austerity.   Austerity measures are the final last ditch effort, futile or not! Back in the day many of us old-timers went through periods of "hard-times". In retrospect I realize there is no comparison to yesteryear hard times and today's version. Back then, expectations were never very high for the working class, there were no sophisticated systems or conveniences anyway. In fact the difference between being "set" or not was about having treats or not. Si...
Post a Comment
Read more

Terrifying Arctic methane levels

A peak methane level of 3026 ppb was recorded by the MetOp-B satellite at 469 mb on December 11, 2021 am. This follows a peak methane level of  3644 ppb  recorded by the MetOp-B satellite at 367 mb on November 21, 2021, pm. A peak methane level of 2716 ppb was recorded by the MetOp-B satellite at 586 mb on December 11, 2021, pm, as above image shows. This image is possibly even more terrifying than the image at the top, as above image shows that at 586 mb, i.e. much closer to sea level, almost all methane shows up over sea, rather than over land, supporting the possibility of large methane eruptions from the seafloor, especially in the Arctic.  Also, the image was recorded later than the image at the top with the 3026 ppb peak, indicating that even more methane may be on the way. This appears to be confirmed by the Copernicus forecast for December 12, 2021, 03 UTC, as illustrated by the image below, which shows methane at 500 hPa (equivalent to 500 mb). Furthermore, ...
Post a Comment
Read more

Women and children overboard

It's the  Catch-22  of clinical trials: to protect pregnant women and children from the risks of untested drugs....we don't test drugs adequately for them. In the last few decades , we've been more concerned about the harms of research than of inadequately tested treatments for everyone, in fact. But for "vulnerable populations,"  like pregnant women and children, the default was to exclude them. And just in case any women might be, or might become, pregnant, it was often easier just to exclude us all from trials. It got so bad, that by the late 1990s, the FDA realized regulations and more for pregnant women - and women generally - had to change. The NIH (National Institutes of Health) took action too. And so few drugs had enough safety and efficacy information for children that, even in official circles, children were being called "therapeutic orphans."  Action began on that, too. There is still a long way to go. But this month there was a sign that ...
Post a Comment
Read more